Bristol Myers Lung Drug Succeeds in Trial
Bristol Myers Squibb announced that a lower dose of its experimental drug admilparant successfully slowed the progression of idiopathic pulmonary fibrosis in a late-stage trial. The 60 mg twice-daily dose outperformed a placebo in preserving lung function after 52 weeks.
Xurve View
Insights:
Xurve View
Bristol-Myers Squibb Co reported that a lower 60 mg dose of its experimental drug admilparant slowed lung-scarring disease progression in a late-stage trial. The therapy stands to become the first of its kind if approved by regulators in the United States. The trial enrolled 1,255 patients to test the oral treatment for idiopathic pulmonary fibrosis.
